Spin-off news

Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone

Alnylam Named #1 Biopharma Employer by Science Magazine

Evotec, Integra Holdings and Yissum establish LAB555 to fast track early-stage drug development

Obesity risk quantification: Lipidomic BMI better than traditional BMI

Alnylam Announces Filing for Marketing Authorization of ONPATTRO® (patisiran) in Brazil for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy